5198-80-1

Basic information

• Product Name: 2-Bromo-4-fomylthiazole
• Synonyms: 2-Bromo-4-formylthiazole AldrichCPR;2-bromothiazole-4-carbaldehyde, 2-bromo-1,3-thiazole-4-carbaldehyde, 2-bromothiazole-4-carboxaldehyde, 2-bromo-4-formylthiazole, 2-bromo-thiazole-4-carbaldehyde, 2-bromo-4-thiazole carboxaldehyde, 2-bromo-4-thiazolecarboxaldehyde;2-BROMO-4-CARBOXYTHIAZOLE;2-BROMO-4-FORMYLTHIAZOLE;2-BROMO-1,3-THIAZOLE-4-CARBOXALDEHYDE;2-BROMOTHIAZOLE-4-CARBALDEHYDE;2-Bromo-4-fomylthiazole;2-BROMOTHIAZOLE-4-CARBALDEHYDE, 95+%
• CAS NO: 5198-80-1
• Molecular Formula: C₄H₂BrNOS
• Molecular Weight: 192.03
• Product Categories: Aldehydes;blocks;Bromides;Thiazoles;Building Blocks;Thiazole;New Products for Chemical Synthesis;C3 to C7;Chemical Synthesis;Heterocyclic Building Blocks
• Mol File: 5198-80-1.mol
• Article Data: 11

Chemical Properties

• Melting Point: 132-135
• Boiling Point: 264.856 °C at 760 mmHg
• Flash Point: 113.981 °C
• Appearance: White to yellow/Crystalline Powder
• Density: 1.921 g/cm³
• Vapor Pressure: 0.009mmHg at 25°C
• Refractive Index: 1.666
• Storage Temp.: Keep Cold
• PKA: -1.37±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-4-fomylthiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-fomylthiazole(5198-80-1)
• EPA Substance Registry System: 2-Bromo-4-fomylthiazole(5198-80-1)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-41-43
• Safety Statements: 26-36/37-39
• WGK Germany: 3
• TSCA: No
• Hazardous Substances Data: 5198-80-1(Hazardous Substances Data)

Usage

General Description

"2-Bromo-4-formylthiazole" is a specific organic compound that belongs to the class of chemically-active substances known as thiazoles. Thiazoles are aromatic compounds containing a five-membered ring that consists of two carbon atoms, one nitrogen atom, and two sulfur atoms. 2-Bromo-4-fomylthiazole is unique due to the presence of a bromine atom and a formyl group attached to the thiazole ring, as suggested by its name. As an organobromine compound (an organic compound containing bromine), it could potentially be utilized in various chemical reactions in research and industry. Its properties, behavior, and potential applications largely depend upon its specific structural attributes.

InChI:InChI=1/C4H2BrNOS/c5-4-6-3(1-7)2-8-4/h1-2H

Upstream product

• 100367-77-9 ethyl 2-bromothiazole-4-carboxylate 
• 5198-86-7 (2-bromo-1,3-thiazol-4-yl)methanol 
• 888314-10-1 2-bromo-N-methoxy-N-methyl-1,3-thiazole-4-carboxamide 

Downstream Products

• 1183405-42-6 2-[4-(trifluoromethoxy)phenyl]-1,3-thiazole-4-carbaldehyde 
• 1183922-66-8 2-(2-fluorophenyl)thiazole-4-carbaldehyde 
• 859850-99-0 2-(3-chlorophenyl)thiazole-4-carbaldehyde 
• 83053-39-8 2'-(2-hydroxyphenyl)-2'-thiazole-4'-carboxaldehyde 
• 749902-11-2 2-(3-methoxyphenyl)thiazole-4-carbaldehyde 
• 885279-11-8 2-(2-methoxyphenyl)thiazole-4-carbaldehyde 
• 174006-70-3 2-(4-(trifluoromethyl)phenyl)thiazole-4-carbaldehyde 
• 20949-81-9 2-phenyl-thiazole-4-carbaldehyde 
• 1187543-47-0 2-amino-4-(2-bromo-1,3-thiazol-4-yl)-6-sulfanylpyridine-3,5-dicarbonitrile 
• 1255940-31-8 (2-bromo-1,3-thiazol-4-yl)(3-methoxyphenyl)methanol 
• 1033865-70-1 (2-bromothiazol-4-ylmethyl)(4-fluorophenyl)amine 
• 5198-86-7 (2-bromo-1,3-thiazol-4-yl)methanol 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured; Formula (I), Formula (II) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.